Severe Fatigue in the First Year Following SARS-CoV-2 Infection: A Prospective Cohort Study

Anouk Verveen, \(^1\) Elke Wynberg, \(^2,3\) Hugo D. G. van Willigen, \(^4\) Anders Boyd, \(^5\) Menno D. de Jong, \(^6\) Godelieve de Bree, \(^7\) Udi Davidovich, \(^6\) Anja Lok, \(^7\) Eric P. Molli van Charante, \(^8\) Hans Knoop, \(^9\) Maria Prins, \(^2,3,9\) and Pythia Nieuwkerk \(^10\); for the RECoVERED Study Group

\(^1\)Department of Medical Psychology, Amsterdam UMC, Amsterdam Public Health Research Institute, University of Amsterdam, Amsterdam, the Netherlands, \(^2\)Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands, \(^3\)Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands, \(^4\)Stichting HIV Monitoring, Amsterdam, the Netherlands, \(^5\)Department of Social Psychology, University of Amsterdam, Amsterdam, the Netherlands, \(^6\)Department of Psychiatry, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, the Netherlands, \(^7\)Department of Public & Occupational Health, Amsterdam UMC, Amsterdam Public Health Research Institute, University of Amsterdam, Amsterdam, the Netherlands, and \(^8\)Department of General Practice, Amsterdam UMC, Amsterdam Public Health Research Institute, University of Amsterdam, Amsterdam, the Netherlands

**Background.** Severe fatigue can persist for months after coronavirus disease 2019 (COVID-19) onset. This longitudinal study describes fatigue severity and its determinants up to 12 months after illness onset across the full spectrum of COVID-19 severity.

**Methods.** RECoVERED, a prospective cohort study in Amsterdam, the Netherlands, enrolled participants aged \(\geq 16\) years after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnosis. Fatigue was measured using the validated Short Fatigue Questionnaire (SFQ; range 4–28) at months 1, 3, 6, 9, and 12 of follow-up. Fatigue severity was modeled over time using mixed-effects linear regression. Determinants of severe fatigue (SFQ \(\geq 18\)) at 6 months since illness onset (ie, persistent fatigue) were identified using logistic regression.

**Results.** Between May 2020 and July 2021, 303 participants completed at least 1 fatigue questionnaire. Twelve months after illness onset, 17.4% (95% CI, 6.7% to 38.3%), 21.6% (95% CI, 11.2% to 37.7%), and 44.8% (95% CI, 28.0% to 62.9%) of participants with mild, moderate, and severe/critical COVID-19 (World Health Organization definition), respectively, experienced severe fatigue. When adjusting for age and sex, having severe/critical COVID-19 (adjusted odds ratio \(\text{aOR}\) = 3.37; 95% CI, 1.28 to 8.93) and low mood at enrollment (\(\text{aOR}\) = 2.43; 95% CI, 1.11 to 5.29) were associated with persistent fatigue. Recovery rarely occurred beyond 6 months after illness onset, regardless of COVID-19 severity.

**Conclusions.** The occurrence of severe fatigue in our cohort was high, especially among those with initially severe/critical COVID-19, with little recovery beyond 6 months after illness onset. Our findings highlight an urgent need for improved understanding of persistent severe fatigue following COVID-19 to help inform prevention and intervention.

**Keywords.** COVID-19; fatigue; infection; persistence; predictors.

Fatigue is among the most commonly reported symptoms of postacute coronavirus disease 2019 (COVID-19) syndrome (PACS). PACS is defined by the World Health Organization (WHO) as the persistence of symptoms at 3 months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, lasting for at least 2 months [1]. Fatigue persisting beyond 6 months after infection is frequently reported among previously hospitalized COVID-19 patients [2–5], and a growing body of evidence suggests that fatigue may also be long-lasting following mild COVID-19 [6, 7].

Persistent fatigue has been linked to other infectious diseases, including Epstein-Barr virus [8], Q-fever [9], influenza [10], and SARS-CoV-1 infection [11]. Estimates of the prevalence of fatigue following COVID-19 vary widely due to differences in the definition of fatigue, study design, and study population [4, 7, 12, 13]. Few studies have measured fatigue using instruments with validated cutoffs for severe fatigue, nor have they explored risk factors for fatigue using prospectively collected longitudinal data [14–16]. Insights into the occurrence, severity, and risk factors of persistent fatigue post-COVID-19 are crucial to understanding and mitigating the long-term consequences of infection.

In this prospective cohort study, we aimed to describe the presence of severe fatigue up to 12 months after illness onset across the full spectrum of COVID-19 severity and identify risk factors.
METHODS

Study Design and Participants
RECoVERED is a cohort study of individuals with SARS-CoV-2 infection in Amsterdam, the Netherlands. Enrollment began on May 11, 2020. Nonhospitalized participants were identified from notification data of laboratory-confirmed SARS-CoV-2 infection at the Public Health Service of Amsterdam and enrolled within 7 days of diagnosis [17]. Prospectively enrolled hospitalized participants were identified from admissions to the COVID-19 wards of the Amsterdam University Medical Centres (AUMC) and enrolled within 7 days of admission. Up to June 30, 2020, a limited number of hospitalized patients were included retrospectively within 3 months after SARS-CoV-2 diagnosis.

Eligibility criteria included laboratory confirmation of SARS-CoV-2 infection by reverse transcriptase polymerase chain reaction (RT-PCR), age 16–85 years, residing in the municipal region of Amsterdam, and adequate understanding of Dutch or English. Nursing home residents were excluded due to inability to attend follow-up appointments. For the present analyses, we included all participants with at least 1 month of follow-up and at least 1 completed fatigue questionnaire by August 1, 2021.

RECoVERED was approved by the medical ethical review board of the AUMC (NL73759.018.20). All participants provided written informed consent.

Study Procedures and Instruments
Study visits at enrollment (D0) and day 7 (D7) of follow-up took place at the participant’s home or hospital ward. Subsequent visits took place at 1 of 2 study sites.

Sociodemographic and Clinical Characteristics
Medical history and sociodemographic data were collected during the first month of follow-up. Data on presence and duration of symptoms (based on the WHO Case Report Form [18]) were collected at the D0, D7, and month 1 visits through participant interview and monthly from month 2 via online questionnaires. Participants rated their anxiety and sadness on a scale from 0 (low) to 10 (high) at the D0 and D7 visits.

Physical measurements (ie, heart rate, respiratory rate [RR], oxygen saturation [SpO₂]) were measured at D0 and D7, or retrieved from hospital records for retrospectively enrolled participants.

At month 1 of follow-up, participants reported their pre-
COVID occupation. Participants in paid employment were asked at month 12 whether they were on long-term leave due to COVID-19 symptoms.

Measurement of Fatigue
At months 1, 3, 6, 9, and 12 of follow-up, participants completed the Short Fatigue Questionnaire (SFQ) [19], which asks participants to rate their agreement on a 7-point scale with 4 statements regarding fatigue in the past 2 weeks [19]. The total SFQ score ranges from 4 to 28. A validated cutoff threshold of 18 defines severe fatigue [20].

Definitions
Persistent severe fatigue was defined as being severely fatigued (SFQ ≥18) 6 months after illness onset [14]. Illness onset was the first day when COVID-19 symptoms were experienced for symptomatic patients or the SARS-CoV-2 diagnosis date for asymptomatic patients. Acute COVID-19 symptoms were those reported within 14 days of illness onset. Clinical severity groups were defined based on WHO COVID-19 severity criteria [21]: mild disease as having an RR <20/min and SpO₂ >94% on room air at both D0 and D7; moderate disease as having an RR 20–30/min and/or SpO₂ 90%–94% or receiving oxygen therapy at D0 or D7; severe disease as having an RR >30/min and/or SpO₂ <90% or receiving oxygen therapy at D0 or D7; critical disease as intensive care unit (ICU) admission due to COVID-19 at any point. High-risk comorbidities were those associated with severe COVID-19 [21]. Body mass index (BMI) was coded as follows: <25, underweight or normal weight; 25–30, overweight; >30, obese. Migration background was categorized as Dutch and non-Dutch based on the country of birth of the participant and their parents [22, 23]; those of non-Dutch background were further classified as originating from a high-income (HIC) or low-/middle-income country (LMIC) [24]. Highest educational level was categorized as none, primary/secondary school, vocational training, or university level. The highest reported anxiety and sadness scores at D0 and D7 (baseline) were categorized as hardly any anxiety/sadness (0 or 1), low (2–5), and high (6–10).

Statistical Analyses
Sociodemographic and clinical characteristics of participants were compared between clinical severity groups. Proportions of participants with severe fatigue and corresponding 95% CIs were calculated among survey responders at months 1, 3, 6, 9, and 12, overall and by clinical severity. The proportions of participants in paid employment on prolonged leave due to COVID-19 at month 12 were compared between those severely fatigued or not using Pearson’s χ² test.

Fatigue severity over time was modeled using linear mixed-effects regression, including a random intercept to account for between-patient variation at baseline. Months since illness onset, age, and sex were included as fixed covariates, regardless of statistical significance. Three multivariable models were constructed: model 1 added sociodemographic and clinical characteristics; model 2 added COVID-19 clinical severity; model 3 added symptoms reported during acute infection (ie, baseline anxiety and sadness, acute fatigue, myalgia, headache, cough, dyspnea, and fever). Variables with a Wald χ² test P value <.20 in the multivariable model with age, sex, and months since illness onset were included in additional models.
onset were included in further multivariable analyses. Each multivariable model was then generated using a backwards selection approach. Adjusted beta-coefficients (aβ) and their 95% CIs are presented, showing the mean difference in fatigue severity compared with the reference value. Changes in fatigue severity following illness onset were compared between baseline and month 6 and between month 6 and month 12 using a Wald χ² test obtained from a model that included age, sex, and clinical severity.

Persistent severe fatigue was modeled using logistic regression. Multivariable model construction was performed as described above. Adjusted odds ratios (aORs) and their 95% CIs are presented. Two sensitivity analyses were performed. First, we restricted our analyses to prospectively enrolled participants. Second, we redefined the outcome as having chronic fatigue (ie, fatigue present within the first month of illness and persisting up to 6 months after illness onset).

Two-sided P values <.05 were considered statistically significant. Statistical analyses were performed using Stata (version 15.1; StataCorp, College Station, TX, USA).

RESULTS

Study Population
Participant flow is described in Supplementary Figure 1. By August 1, 2021, 350 participants had been enrolled. Forty-seven participants did not complete a fatigue questionnaire. Consequently 303 participants were included in our analyses (Table 1). None of the participants had been vaccinated for COVID-19 before enrollment. There were no statistically significant differences in sociodemographic and clinical characteristics between participants who were excluded vs included in our analyses (Supplementary Table 1a). The proportion of missing surveys during follow-up is displayed in Supplementary Figure 2. Between those who were later to follow-up and those who remained in the study, the sex (50% male vs 58%; P = .330), number of comorbidities (P = .100), clinical severity (P = .415), and proportion of participants reporting severe fatigue in their first completed survey (65% vs 50%, respectively; P = .081) did not differ. However, participants who were lost to follow-up (LTFU) were on average 8 years younger than those who remained in active follow-up (β = -7.96; P = .003).

Severe Fatigue and Paid Employment
The occurrence of severe fatigue among participants with mild, moderate, and severe/critical disease who completed the SFQ was 39.7% (95% CI, 29.2% to 51.3%), 63.7% (95% CI, 54.0% to 72.5%), and 62.2% (95% CI, 45.7% to 76.2%) 1 month after illness onset, respectively; this decreased to 24.7% (95% CI, 16.1% to 35.8%), 42.7% (95% CI, 34.3% to 51.6%), and 45.9% (95% CI, 33.8% to 58.5%) by 3 months after illness onset (Figure 1). One year after illness onset, approximately one-fifth of those with mild or moderate disease had severe fatigue (17.4%; 95% CI, 6.7% to 38.3%; and 21.6%; 95% CI, 11.2% to 37.7%; respectively) compared with 44.8% (95% CI, 28.0% to 62.9%) of those with severe/critical disease.

Before SARS-CoV-2 infection, most study participants (193/303; 64%) had paid employment (Table 1). Of these 193, 52 (26.9%) reached their month 12 study visit and completed the questionnaire on long-term leave. Thirty-eight percent (6/16) of those with severe fatigue at month 12 were either fully or partially on long-term leave, whilst this proportion was 11% (4/36) for those without severe fatigue at month 12 (P < .026).

Factors Associated With Fatigue Severity Over Time
In the linear mixed-effects Model 1, participants who were female, obese, originated from LMICs, or had ≥3 comorbidities at illness onset had significantly higher mean fatigue severity scores compared with their respective reference groups, when adjusting for age and time since illness onset (Table 2; Supplementary Figure 3a). When adjusting for clinical severity in Model 2, BMI and migration background were no longer statistically significant (Supplementary Table 2), but female participants continued to have higher mean fatigue severity scores than males (aβ, 2.21; 95% CI, 0.78 to 3.64) (Table 2). Participants with moderate (aβ, 3.37; 95% CI, 1.72 to 5.03) or severe/critical disease (aβ, 4.39; 95% CI, 2.35 to 6.42) experienced significantly higher fatigue severity than those with mild disease (Table 2; Supplementary Figure 3b). In Model 3, participants with dyspnea in the acute phase (aβ, 2.47; 95% CI, 1.01 to 3.93), a high level of baseline sadness (aβ, 3.25; 95% CI, 1.40 to 4.90), severe/critical disease (aβ, 3.17; 95% CI, 1.11 to 5.22), and ≥3 comorbidities (aβ, 4.41; 95% CI, 1.64 to 7.18) had higher mean SFQ scores when adjusting for age and sex (Table 2; Supplementary Figure 3c). A statistically significant decline in fatigue severity was observed in the first 6 months after illness onset (aβ, –4.32; 95% CI, –5.29 to –3.35), but no further decrease was observed between month 6 and month 12 (P = .561).

Risk Factors for Persistent Severe Fatigue at 6 Months After Illness Onset
Six months after illness onset, 28.4% (95% CI, 22.4% to 35.0%) of participants were severely fatigued (Figure 1). In the logistic regression Model 1, the odds of having persistent severe fatigue were higher in those with ≥3 comorbidities compared with no comorbidities (aOR, 4.38; 95% CI, 1.40 to 13.74) (Figure 2). In Model 2, those with severe/critical COVID-19 had higher odds of developing persistent severe fatigue than those with mild disease (aOR, 3.51; 95% CI, 1.37 to 8.96). In Model 3, a high level of baseline sadness (aOR, 2.43; 95% CI, 1.11 to 5.29) and severe/critical COVID-19 (aOR, 3.37; 95% CI, 1.28 to 8.93) were independently associated with persistent severe fatigue.

Results were comparable when restricting the analyses to prospectively enrolled participants (Supplementary Table 3a).
Table 1. Sociodemographic, Clinical, and Study Characteristics of Recovered Study Participants Enrolled Between May 2020 and August 2021, Amsterdam, the Netherlands, by COVID-19 Clinical Severity

|                         | Total (n = 303) | Mild COVID-19 (n = 88) | Moderate COVID-19 (n = 136) | Severe/Critical COVID-19 (n = 79) |
|-------------------------|-----------------|------------------------|-----------------------------|----------------------------------|
| **Sociodemographic features** |                 |                        |                             |                                  |
| Sex                     |                 |                        |                             |                                  |
| Male                    | 173 (57)        | 44 (50)                | 79 (58)                     | 50 (63)                          |
| Female                  | 130 (43)        | 44 (50)                | 57 (42)                     | 29 (37)                          |
| Age, y                  | 51.0 (36.0–62.0)| 40.0 (27.5–54.5)       | 49.0 (34.0–60.5)            | 60.0 (50.0–66.0)                 |
| BMI, kg/m²              | 26.1 (23.2–29.4)| 24.6 (22.8–27.7)       | 26.2 (23.5–29.4)            | 27.3 (25.6–32.9)                 |
| **BMI category**        |                 |                        |                             |                                  |
| Normal weight           | 124 (41)        | 50 (57)                | 56 (41)                     | 18 (23)                          |
| Overweight              | 106 (35)        | 24 (27)                | 48 (35)                     | 34 (43)                          |
| Obese                   | 69 (23)         | 13 (15)                | 32 (24)                     | 24 (30)                          |
| Missing                 | 4 (1)           | 1 (1)                  | 0 (0)                       | 3 (4)                            |
| Migration background (OECD) |              |                        |                             |                                  |
| Dutch                   | 184 (61)        | 63 (72)                | 78 (57)                     | 43 (54)                          |
| Non-Dutch, OECD HIC     | 37 (12)         | 12 (14)                | 21 (15)                     | 4 (5)                            |
| Non-Dutch, OECD LMIC    | 73 (24)         | 10 (11)                | 34 (25)                     | 29 (37)                          |
| Missing                 | 9 (3)           | 3 (3)                  | 3 (2)                       | 3 (4)                            |
| Smoking                 |                 |                        |                             |                                  |
| Nonsmoker               | 191 (63)        | 54 (61)                | 81 (60)                     | 56 (71)                          |
| Smoker                  | 20 (7)          | 8 (9)                  | 11 (8)                      | 1 (1)                            |
| Ex-smoker               | 87 (29)         | 23 (26)                | 43 (32)                     | 21 (27)                          |
| Missing                 | 5 (2)           | 3 (3)                  | 3 (2)                       | 3 (4)                            |
| Highest level of education |              |                        |                             |                                  |
| None, primary or secondary education | 42 (14) | 7 (8)                  | 24 (18)                     | 11 (14)                          |
| Vocational training     | 73 (24)         | 9 (10)                 | 34 (25)                     | 30 (38)                          |
| University education    | 178 (59)        | 69 (78)                | 75 (55)                     | 34 (43)                          |
| Missing                 | 10 (3)          | 3 (3)                  | 3 (2)                       | 4 (5)                            |
| Work situation before COVID-19 |        |                        |                             |                                  |
| Paid employment or self-employed | 193 (64) | 64 (73)                | 87 (64)                     | 42 (53)                          |
| On sick leave           | 15 (5)          | 0 (0)                  | 6 (4)                       | 9 (11)                           |
| Retired                 | 37 (12)         | 9 (10)                 | 16 (12)                     | 12 (15)                          |
| Other                   | 50 (17)         | 14 (16)                | 23 (17)                     | 13 (16)                          |
| Missing                 | 8 (3)           | 1 (1)                  | 4 (3)                       | 3 (4)                            |
| No. of COVID-19 high-risk comorbidities |        |                        |                             |                                  |
| 0                       | 168 (55)        | 63 (72)                | 81 (60)                     | 24 (30)                          |
| 1                       | 71 (23)         | 17 (19)                | 29 (21)                     | 25 (32)                          |
| ≥2                      | 38 (13)         | 5 (6)                  | 17 (13)                     | 16 (20)                          |
| Cardiovascular disease  | 81 (27)         | 12 (14)                | 33 (24)                     | 36 (46)                          |
| Diabetes                | 34 (11)         | 5 (6)                  | 11 (8)                      | 18 (23)                          |
| Chronic respiratory disease | 20 (7)      | 1 (1)                  | 8 (6)                       | 11 (14)                          |
| Cancer                  | 17 (6)          | 6 (7)                  | 7 (5)                       | 4 (5)                            |
| Immunosuppressed        | 6 (2)           | 0 (0)                  | 3 (2)                       | 3 (4)                            |
| Psychiatric illness     | 18 (6)          | 5 (6)                  | 9 (7)                       | 4 (5)                            |
| Other comorbidities     | 64 (21)         | 11 (13)                | 34 (25)                     | 19 (24)                          |
| **Clinical features of SARS-CoV-2 infection** |       |                        |                             |                                  |
| Symptom status at baseline |            |                        |                             |                                  |
| Symptomatic             | 302 (100)       | 87 (99)                | 136 (100)                   | 79 (100)                         |
| Asymptomatic            | 1 (0)           | 1 (1)                  | 0 (0)                       | 0 (0)                            |
| Hospital admission      | 144 (48)        | 4 (5)                  | 64 (47)                     | 76 (96)                          |
| ICU admission           | 39 (13)         | 0 (0)                  | 0 (0)                       | 39 (49)                          |
| Days from illness onset to SARS-CoV-2 diagnosis | 4 (2–10) | 3 (1–8)                | 5 (2–11)                    | 7 (2–11)                         |

*P* values are calculated using chi-square tests or Fisher’s exact tests for categorical variables and Wilcoxon rank sum tests for continuous variables.
Table 1. Continued

|                          | Total  | Mild     | Moderate | Severe/Critical | PValue |
|--------------------------|--------|----------|----------|-----------------|--------|
| n = 303                  |        |          |          |                 |        |
| Days from illness onset to hospitalization | 9 (7–14) | 24 (9–66) | 9 (8–15) | 9 (7–13) | .24    |
| Days from illness onset to ICU admission | 10 (8–12) | NA       | NA       | 10 (8–12) |        |
| Received oxygen therapy before or during follow-up | 137 (45) | 0 (0)    | 63 (46)  | 74 (95) | <.001  |
| Physical measurementsa |        |          |          |                 |        |
| Maximal HR, beats/min   | 82 (72–94) | 76 (66–81) | 84 (76–94) | 94 (79–107) | <.001  |
| Maximal RR, breaths/min | 20 (16–24) | 16 (16–16) | 20 (20–24) | 25 (20–32) | <.001  |
| Lowest SpO2, %          | 96 (92–98) | 98 (97–99) | 96 (93–98) | 88 (81–90) | <.001  |
| Highest baseline sadness scoref |        |          |          |                 | <.001  |
| 0–1                     | 125 (41) | 40 (45)  | 44 (32)  | 41 (52) |        |
| 2–5                     | 90 (30)  | 35 (40)  | 43 (32)  | 12 (15) |        |
| 6–10                    | 81 (27)  | 13 (15)  | 45 (33)  | 23 (29) |        |
| Missing                 | 7 (2)   | 0 (0)    | 4 (3)    | 3 (4)   |        |
| Highest baseline anxiety scoref |        |          |          |                 | <.001  |
| 0–1                     | 131 (43) | 48 (55)  | 43 (32)  | 40 (51) |        |
| 2–5                     | 86 (28)  | 28 (32)  | 47 (35)  | 11 (14) |        |
| 6–10                    | 80 (26)  | 12 (14)  | 42 (31)  | 26 (33) |        |
| Missing                 | 6 (2)   | 0 (0)    | 4 (3)    | 2 (3)   |        |
| Acute presence of symptomg |        |          |          |                 |        |
| Fatigue                 | 243 (80) | 71 (81)  | 108 (79) | 64 (81) | .95    |
| Myalgia                 | 156 (51) | 49 (56)  | 76 (56)  | 31 (39) | .040   |
| Cough                   | 186 (61) | 52 (59)  | 83 (61)  | 51 (65) | .76    |
| Fever                   | 175 (58) | 46 (52)  | 79 (58)  | 50 (63) | .35    |
| Dyspnea                 | 173 (57) | 34 (39)  | 83 (61)  | 56 (71) | <.001  |
| Headache                | 157 (52) | 53 (60)  | 79 (58)  | 25 (32) | <.001  |
| Vaccinated at enrollment | 0 (0)   | 0 (0)    | 0 (0)    | 0 (0)   | NA     |
| Vaccinated during follow-up | 217 (72) | 66 (78)  | 93 (68)  | 56 (72) | .28    |
| Time from illness onset to first vaccination, d | 246 (144–361) | 197 (130–302) | 247 (164–314) | 372 (139–393) | .007 |
| Died during follow-up   | 0       | 0        | 0        | 0       | NA     |

Place of recruitment

|                          | Nonhospital (public health service) | Hospital |
|--------------------------|------------------------------------|----------|
| n = 150                  | 77 (88)                            | 69 (51)  |
| n = 153                  | 11 (13)                            | 67 (49)  |
| Type of inclusion        | Prospective                         | Retrospective |
| n = 218                  | 76 (86)                            | 12 (14)  |
| n = 85                   | 105 (77)                           | 31 (23)  |
| Days from illness onset to inclusion in study | 12 (6–51) | 6 (4–12) | 12 (7–33) | 40 (14–89) | <.001 |
| n = 15                | 9 (5–14)                           | 6 (4–9)  | 9 (6–16) | 14 (10–18) | <.001 |
| n = 85                   | 66 (94)                            | 84 (74–92) | 88 (73–97) | .56    |
| Follow-up time from enrollment in study | 292.0 (194.0–405.0) | 292.0 (209.0–402.0) | 284.5 (190.5–403.0) | 319.0 (136.0–410.0) | .85 |
| LT Fu                 | 40                                 | 13       | 19       | 7       | NA     |

Continuous variables are presented as median (IQR) and compared using the Kruskal-Wallis test; categorical and binary variables presented as No. (%) and compared using the Pearson χ² test (or Fisher exact test if n < 5). COVID-19 clinical severity groups defined as follows: mild as having an RR <20/min and SpO₂ on room air >94% at both day 0 and day 7; moderate disease as having an RR of 20–30/min, SpO₂ 90%–94%, and/or receiving oxygen therapy at day 0 or day 7; severe disease as having an RR >30/min or SpO₂ <90% at day 0 or day 7; critical disease as requiring ICU admission. COVID-related comorbidities are based on WHO Clinical Management Guidelines and include cardiovascular disease (including hypertension), chronic pulmonary disease (excluding asthma), renal disease, liver disease, cancer, immunosuppression (excluding HIV, including previous organ transplantation), previous psychiatric illness, and dementia.

Abbreviations: BMI, body mass index; COVID-19, coronavirus disease 2019; HIC, high-income country; HR, heart rate; ICU, intensive care unit; IQR, interquartile range; LMIC, low- or middle-income country; LTFU, loss to follow-up; NA, not applicable; OECD, Organisation for Economic Co-operation and Development; RR, respiratory rate; SpO₂, oxygen saturation; WHO, World Health Organization.

*Normal BMI group includes 3 individuals with BMI between 18.0 and 18.5 kg/m².

Migration background was based on country of birth of participant and that of their parents and included first- and second-generation migrants.

*Cohort data is based on unemployed, receiving welfare or benefits, homemaker, student.

COVID-related comorbidities are based on WHO Clinical Management Guidelines and include cardiovascular disease (including hypertension), chronic pulmonary disease (excluding asthma), renal disease, liver disease, cancer, immunosuppression (excluding HIV, including previous organ transplantation), previous psychiatric illness, and dementia.

*Physical measurements at D0 and D7 study visits. Oxygen saturation measured on room air if possible or retrieved from ambulance records for hospitalized participants admitted on oxygen on day of enrollment.

*Highest baseline anxiety and sadness scores defined as the highest reported level of anxiety or sadness at D0 and D7 subjectively reported on a scale from 0 to 10.

*Acute presence of a symptom defined as reporting it during the first 2 weeks after overall illness onset.

*LT Fu defined as active withdrawal from the study or 2 consecutive no-show appointments despite 3 attempts to establish contact.
When redefining the outcome to having chronic fatigue, the effect size of severe/critical COVID-19 became stronger (aOR, 5.18; 95% CI, 1.73 to 15.5; from aOR, 3.51; 95% CI, 1.37 to 8.96; in Model 2; aOR, 5.22; 95% CI, 1.68 to 16.2; from aOR, 3.37; 95% CI, 1.28 to 8.93; in Model 3) with minimal change in the effect size of other covariates (Supplementary Table 3b).

**DISCUSSION**

This is the first prospective cohort study on clinically severe fatigue (measured using a validated instrument) up to 12 months after illness onset in COVID-19 patients across the full spectrum of COVID-19 severity. The occurrence of severe fatigue in our cohort was high, particularly during the first 6 months after infection. Even after 1 year from COVID-19 disease onset, severe fatigue was reported by 17%, 22%, and 45% of participants with initially mild, moderate, and severe/critical COVID-19 illness, respectively. As these individuals were significantly more likely to take long-term leave compared with those without severe fatigue at month 12, the socio-economic consequences of persistent fatigue following COVID-19 could be substantial. Risk factors for higher fatigue severity during the first year...
### Table 2. Determinants of Higher Fatigue Severity Over Time (Linear Mixed-Effects Models)

| Determinant (Selected a Priori) | Multivariable Model 1<sup>a</sup> | Multivariable Model 2<sup>a</sup> | Multivariable Model 3<sup>a</sup> |
|---------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                 | β Coef. (95% CI)                  | P Value                         | β Coef. (95% CI)                  | P Value                         | β Coef. (95% CI)                  | P Value                         |
| Time since illness onset, mo    | -0.35 (-0.45 to -0.25)           | <.001                           | -0.35 (-0.44 to -0.25)           | <.001                           | -0.33 (-0.42 to -0.23)           | <.001                           |
| Sociodemographic and medical characteristics at illness onset | | | | | | |
| Age per 10-y increase, y        | -0.12 (-0.66 to 0.43)            | 590                             | -0.03 (-0.88 to 0.02)            | 173                             | -0.03 (-0.08 to 0.02)            | 174                             |
| Sex                             |                                  | 0.25                             |                                  | 0.04                             |                                  | 0.057                           |
| Male                            | Ref.                             |                                  | Female                          | Ref.                             |                                  |                                  |
| Female                          | 2.21 (0.78 to 3.64)              |                                  |                                  | 1.48 (0.07 to 2.90)             |                                  |                                  |
| BMI group                       |                                  | 0.21                             |                                  | n.s.                            | n.s.                            | n.s.                            |
| Normal weight                   | Ref.                             |                                  |                                  |                                  |                                  |                                  |
| Overweight                      | 2.09 (0.37 to 3.81)              |                                  |                                  | n.s.                            | n.s.                            | n.s.                            |
| Obese                           | 2.26 (0.31 to 4.20)              |                                  |                                  | n.s.                            | n.s.                            | n.s.                            |
| No. of high-risk COVID-19 comorbidities at illness onset<sup>b</sup> | | | | | | |
| 0                               |                                  | 0.02                             |                                  | 0.03                             |                                  | 0.07                            |
| 1                               | 1.41 (0.53 to 3.35)              | 1.53 (0.32 to 3.38)             |                                  | 0.59 (1.24 to 2.41)             |                                  |                                  |
| 2                               | 1.14 (1.26 to 3.55)              | 1.16 (1.16 to 3.49)             |                                  | 0.95 (1.35 to 3.25)             |                                  |                                  |
| 3+                              | 4.91 (2.02 to 7.79)              | 4.93 (2.12 to 7.75)             |                                  | 4.41 (1.64 to 7.18)             |                                  |                                  |
| Migration background<sup>c</sup>|                                  | 0.08                             |                                  | n.s.                            | n.s.                            | n.s.                            |
| Dutch                           | Ref.                             |                                  |                                  | n.s.                            | n.s.                            | n.s.                            |
| Non-Dutch, OECD high-income     | 1.81 (0.44 to 4.06)              |                                  |                                  | n.s.                            | n.s.                            | n.s.                            |
| Non-Dutch, OECD LMIC           | 2.03 (0.29 to 3.76)              |                                  |                                  | n.s.                            | n.s.                            | n.s.                            |
| Clinical severity              | COVID-19 Clinical severity<sup>d</sup>|                                  |                                  | 3.37 (1.72 to 5.03)             | 2.13 (0.48 to 3.79)             | 3.17 (1.11 to 5.22)             |
| Mild                            | NA                               | NA                               | Ref.                             |                                  |                                  |                                  |
| Moderate                       | NA                               | NA                               |                                  |                                  |                                  |                                  |
| Severe/critical                | NA                               | 4.39 (2.35 to 6.42)             |                                  |                                  |                                  |                                  |
| Clinical features of COVID-19   | Highest baseline sadness score<sup>e</sup> |                                  |                                  | 3.15 (1.40 to 4.90)             | 3.17 (1.11 to 5.22)             |                                  |
| 0–1                            | NA                               | NA                               | NA                               | NA                               | NA                               | <.001                           |
| 2–5                            | NA                               | NA                               | NA                               | NA                               | NA                               | Ref.                            |
| 6–10                           | NA                               | NA                               | NA                               | 1.00 (0.65 to 1.65)             |                                  |                                  |
| Presence of acute dyspnea<sup>f</sup> |                                  |                                  |                                  | 3.15 (1.40 to 4.90)             |                                  |                                  |
| No                             | NA                               | NA                               | NA                               | NA                               | NA                               | Ref.                            |
| Yes                            | NA                               | NA                               | NA                               | NA                               | 2.47 (1.01 to 3.93)             |                                  |

Abbreviations: COVID-19, coronavirus disease 2019; ICU, intensive care unit; NA, not applicable; n.s., not statistically significant; RR, respiratory rate; SpO<sub>2</sub>, oxygen saturation; WHO, World Health Organization.

<sup>a</sup>Sequential addition of groups of covariates, described as follows: Model 1: sociodemographic and medical characteristics at illness onset. Model 2: sociodemographic and medical characteristics at illness onset + clinical severity. Model 3: sociodemographic and medical characteristics at illness onset + clinical severity + clinical features of COVID-19.

<sup>b</sup>COVID-related comorbidities are based on the WHO Clinical Management Guidelines [16] and include cardiovascular disease (including hypertension), chronic pulmonary disease (excluding asthma), renal disease, liver disease, cancer, immunosuppression (excluding HIV, including previous organ transplantation), previous psychiatric illness, and dementia.

<sup>c</sup>Migration background was based on country of birth of participant and that of their parents and included first- and second-generation migrants.

<sup>d</sup>Clinical severity groups defined as follows: mild as having an RR <20/min and SpO<sub>2</sub> on room air >94% at both day 0 and day 7; moderate disease as having an RR 20–30/min, SpO<sub>2</sub> 90%–94%, and/or receiving oxygen therapy at day 0 or day 7; severe disease as having an RR >30/min or SpO<sub>2</sub> <90% at day 0 or day 7; critical disease as requiring ICU admission.

<sup>e</sup>Highest baseline sadness score defined as the highest reported level of sadness at D0 or D7, subjectively reported on a scale from 0 to 10.

<sup>f</sup>Acute presence of a symptom defined as reporting it during the first 2 weeks after overall illness onset.
## Baseline Characteristics

|                          | aOR (95% CI) | P Value |
|--------------------------|--------------|----------|
| **Age, y**               |              |          |
| Age (per 10-y increase)  | 0.94 (0.75−1.18) | .537     |
| **Sex**                  |              |          |
| Male                     | Ref.         | .198     |
| Female                   | 1.55 (0.82−2.94) |          |
| **No. of comorbidities** |              |          |
| 0                        | Ref.         | .015     |
| 1                        | 1.46 (0.66−3.23) |          |
| 2                        | 1.74 (0.59−5.10) |          |
| 3 or more                | 4.38 (1.40−13.74) |          |

### Model 2

## Baseline Characteristics and Clinical Severity

|                          | aOR (95% CI) | P Value |
|--------------------------|--------------|----------|
| **Age, y**               |              | .671     |
| Age (per 10-y increase)  | 0.95 (0.76−1.18) |          |
| **Sex**                  |              | .168     |
| Male                     | Ref.         |          |
| Female                   | 1.57 (0.83−2.97) |          |
| **Clinical severity**    |              | .010     |
| Mild                     | Ref.         |          |
| Moderate                 | 1.71 (0.81−3.60) |          |
| Severe/critical          | 3.51 (1.37−8.96) |          |

### Model 3

## Baseline Characteristics, Clinical Severity, and Symptoms

|                          | aOR (95% CI) | P Value |
|--------------------------|--------------|----------|
| **Age, y**               |              | .687     |
| Age (per 10-y increase)  | 0.90 (0.71−1.14) |          |
| **Sex**                  |              | .304     |
| Male                     | Ref.         |          |
| Female                   | 1.49 (0.77−2.91) |          |
| **Clinical severity**    |              | .010     |
| Mild                     | Ref.         |          |
| Moderate                 | 1.43 (0.63−3.12) |          |
| Severe/critical          | 3.37 (1.28−8.93) |          |
| **Baseline sadness score** |              | .045     |
| 0−1                      | Ref.         |          |
| 2−5                      | 0.76 (0.34−1.73) |          |
| 6−10                     | 2.43 (1.11−5.29) |          |

---

**Figure 2.** COVID-19 clinical severity defined as follows: mild disease as having a RR <20/min and SpO\(_2\) >94% on room air at both D0 and D7 study visits; moderate disease as having a RR 20–30/min and SpO\(_2\) 90–94% or receiving oxygen therapy at D0 and/or D7 study visits; severe disease as having a RR >30/min and SpO2 <90% or receiving oxygen therapy at D0 and/or D7 study visits; critical disease as requiring ICU admission as a result of COVID-19 at any point. Highest baseline sadness score defined as the highest reported level of sadness at D0 or D7, subjectively reported on a scale from 0 to 10. Abbreviation: aOR, adjusted odds ratio.
 included having multiple comorbidities, more severe COVID-19, acute dyspnea, and a high level of baseline sadness.

Owing to its prospective longitudinal design, our study provides valuable insight into temporal changes in post-COVID-19 fatigue. The proportion of participants with severe fatigue was highest in the moderate and severe/critical groups at all time points. Although a significant decline in fatigue severity was observed between months 0 and 6 after illness onset, measurements stabilized between months 6 and 12, also for those with initially mild COVID-19, suggesting poor prognosis beyond this point. Indeed, among those with mild COVID-19, approximately one-fifth developed persistent severe fatigue. It is not evident whether this proportion differs from the general Dutch population as we lacked an appropriate comparison group [25]. However, as those with mild disease represent the largest proportion of COVID-19 patients globally, millions worldwide may be experiencing severe fatigue after COVID-19. In addition to ongoing efforts to prevent new SARS-CoV-2 infections, identifying effective interventions for persistent severe fatigue that can be readily scaled up should therefore be a research priority.

We identified several risk factors for fatigue severity following SARS-CoV-2 infection, several of which are modifiable and provide scope for risk reduction. First, having multiple comorbidities was an independent risk factor. Previous studies have also reported a relationship between comorbidities and postinfectious fatigue [25], with comorbidities probably both lying on the causal pathway and partly representing preexisting fatigue. These findings add to the multitude of reasons why prevention of noncommunicable diseases, such as cardiovascular disease and diabetes, is crucial for public health worldwide, not only during a pandemic. Dyspnea during the acute phase of infection was also independently associated with fatigue severity. Since many participants with acute dyspnea experience persistent dyspnea as part of PACS [17], the association between dyspnea and fatigue may be a direct consequence of acute respiratory distress syndrome and ongoing reduced functional capacity due to lung tissue damage [26, 27]. Underlying contributing factors including lung pathology should be a focus of future research.

Interestingly, reporting a high level of sadness was identified as an independent risk factor for fatigue severity over time. Explaining this finding is challenging, as fatigue is both a known symptom of depression and, in turn, depression can be a reaction to persistent fatigue [25]. Additionally, other symptoms of depression, such as sleep disorders and concentration problems, have been reported as long-term sequelae of COVID-19 disease [28, 29] and may be associated with severe fatigue. The association between sadness levels and fatigue severity following COVID-19 is not likely explained by preexisting clinical depression as only 18/303 (6%) of our participants reported a previous psychiatric diagnosis.

We did not explore the contribution of underlying biochemical, hormonal, or body system (eg, lung, cardiac, neurological, or psychological) abnormalities to fatigue in our study participants. To date, the pathogenesis of postinfectious fatigue is largely unknown. Several theories have been proposed, which include end-organ damage, ongoing inflammation, changes in skeletal muscle morphology and function, and neurological causes [30]. Others have also described psychological factors, such as cognitive and behavioral responses to acute illness and cultural factors [30]. Regardless of its cause, persistent severe fatigue can have serious consequences for the individual as well as impact health care usage and the economic productivity of a population [31, 32]. Unsurprisingly, the predictors of persistent severe fatigue largely matched the factors associated with fatigue severity over time. Future studies should further elucidate predictors of persistent severe fatigue post-COVID-19 to target active prevention against SARS-CoV-2 infection for those at highest risk for post-COVID-19 fatigue.

Our study has several strengths. Our prospective cohort study follows individuals from disease onset, minimizing the selection bias resulting from individuals self-referring after the onset of persistent fatigue. Furthermore, by including both hospitalized and nonhospitalized patients, we captured the entire spectrum of severity of COVID-19. Another strength is our long follow-up length and use of a validated instrument to assess fatigue [20, 33]. An important limitation of our study is that levels of fatigue pre-COVID-19, for example, due to other chronic illnesses, were unknown. In addition, due to a lack of COVID-negative controls, we cannot infer what proportion of fatigue was directly attributable to SARS-CoV-2 infection, as opposed to a result of lockdown restrictions, coined “pandemic fatigue” [34]. Another limitation is that analysis of the prevalence of, and risk factors for, severe fatigue may be influenced by differential LTFU of participants and missing survey data. The direction of bias in prevalence estimates depends on whether fatigue severity influenced the likelihood to drop out or skip surveys. When comparing the sex, number of comorbidities, clinical severity, and proportion of participants reporting severe fatigue in their earliest completed survey, no difference was found between those who were later lost to follow-up and those who remained in the study. However, those who were LTFU were generally younger than those who remained in active follow-up. Although we cannot rule out that attrition of these younger participants may have resulted in an overexaggeration of severe fatigue prevalence estimates, the lack of difference observed in other baseline variables, notably initial fatigue prevalence, suggests that this retention bias is unlikely to be substantial. Finally, within our cohort, those who did not complete the month 6 survey were more likely to be of non-Dutch than Dutch origin ($P = .005$) (Supplementary Table 1b), and therefore migrant groups were underrepresented in the persistent fatigue analysis.
The occurrence of severe fatigue in our cohort was high, particularly among participants with severe/critical COVID-19. Although a decline in fatigue severity was observed in the first 6 months after illness onset, fatigue severity subsequently stabilized, indicating poor prognosis beyond this point. Participants with severe/critical COVID-19, multiple comorbidities, and high baseline sadness levels are at increased risk of persistent severe fatigue, a condition that may have substantial socio-economic implications. Our findings highlight an urgent need for improved understanding of the causes of persistent severe fatigue following COVID-19 in order to develop effective strategies for prevention.

Acknowledgments

The authors wish to thank all RECoVERED study participants.

Financial support. This publication is part of the project RECoVERED with project number 10150062010002 of the research programme Infectieziektetestrijding 3 2019-2023, which is financed by the Netherlands Organisation for Health Research and Development (ZonMw). Additionally, it is part of the project “Long-term Mental Health Trajectories in Recovered COVID-19 Patients: Exploring the Interplay of Psychosocial and Biological Factors Affecting Health-Related Quality of Life” with project number 10430032010010 of the research programme COVID-19, financed by ZonMw. This work was additionally supported by the Public Health Service of Amsterdam (Research & Development grant number 21-14). H.K. received additional funding from “ReCoVer: A Randomised Controlled Trial testing the efficacy of Cognitive Behavioural Therapy for preventing chronic post-infectious fatigue among patients diagnosed with COVID-19” with project number 10430012010025 of the research programme COVID-19, financed by ZonMw.

Potential conflicts of interest. A.B. received a grant from ANRS in the past 36 months and participated in the Data Safety Monitoring Board or Advisory Board for ZonMw for a study conducted by the Amsterdam University Medical Centers, location Amsterdam Medical Center. G.D.B. served as a paid member of the Scientific Advisory Board of ExcViR in the past 36 months and is a patent holder of INV 2020-039 both through their institution. All other authors report no potential conflicts.

Author contributions. P.N. led the Psychosocial Study Group within the RECoVERED cohort study, of which P.N., M.P., H.K., E.M.v.C., A.L., U.D., A.V., and E.W. were key members. For the present study, E.W., A.V., H.K., M.P., and P.N. conceptualized the research question and analyses. E.W., A.V., A.B., and P.N. conducted the formal analysis and data visualisation. F.E.L.A. and A.V. drafted the initial manuscript. All authors read a draft of the manuscript and provided feedback, contributed to interpretation of the data, and approved the final manuscript. E.W., A.V., and H.v.W. contributed to the data collection and curation and coordinated the RECoVERED cohort study. G.D.B., M.d.I., and M.P. led the RECOVERED study. G.D.B., M.d.I., M.P., and P.N. secured study financing and medical ethical approval.

Patient consent. All participants in the RECoVERED study provided written informed consent. The design of the study was approved by the local medical ethics committee.

RECOVERED Study Group. Public Health Service of Amsterdam: Ivette Agard, Jane Ayal, Floor Cavdar, Marianne Craenen, Annemarieke Deuring, Annelies van Dijk, Ertan Ersan, Laura del Grande, Joost Hartman, Nelleke Koedoot, Tjalling Leenstra, Romy Lebbink, Dominique Loomans, Agata Makowska, Tom du Maine, Ilja de Man, Amy Matser, Lizenka van der Meij, Marleen van Polanen, Mario Oud, Clark Reid, Leenanny Storey, Marc van Rijk, Marjan van Wijk. Amsterdam University Medical Centers: Joost van den Aardweg, Joyce van Assem, Marjine van Beek, Thuya Blankert, Marjaert Dijkstra, Oriana Figaroa, Leah Frenkel, Marit van Gils, Jelle van Haga, Xiaochuan (Alvin) Han, Agnes Harksamp-Holwerda, Mette Hazenberg, Soemeja Hidad, Nina de Jong, Neeltje Kootstra, Lara Kuitj, Colin Russell, Karijn van der Staken, Annelou van der Veen, Bas Verkaal, Gerben-Bienk Visser.

References

1. World Health Organization. A clinical case definition of post-COVID-19 condition by a Delphi consensus. 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post-COVID-19-conditionClinical_caseDefinition-2021.1
2. Fortini A, Torrigiani A, Sharagli S, et al. COVID-19: persistence of symptoms and lung alterations after 3-6 months from hospital discharge. Infection. 2021; 49(5):1007–1015. doi: 10.1007/s10152-021-01638-1. Epub 2021 Jun 6. PMID: 34091869; PMCID: PMC8179958.
3. Garrigues E, Janvier P, Khrairi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect 2020; 81:e4–6.
4. Morin L, Savale I, Pham T, et al. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA 2021; 325:1525–34.
5. Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One 2020; 15:e0240784.
6. Petersen MS, Kristiansen MF, Hanusson KD, et al. Long COVID in the Faroe Islands - a longitudinal study among non-hospitalized patients. Clin Infect Dis. 2021; 73(11):e4058–e4063. doi:10.1093/cid/ciaa1792. PMID: 33252665; PMCID: PMC7799340.
7. Stavem K, Ghaniwma N, Olsen MK, Gilboe HM, Envik G. Prevalence and determinants of fatigue after COVID-19 in non-hospitalized subjects: a population-based study. Int J Environ Res Public Health. 2021; 18(4):2030. doi:10.3390/ijerph18042038. PMID: 33607614; PMCID: PMC7921928.
8. Kristiansen MS, Stabursvik J, O’Leary EC, et al. Clinical symptoms and markers of disease mechanisms in adolescent chronic fatigue following Epstein-Barr virus infection: an exploratory cross-sectional study. Brain Behav Immun 2019; 80:551–63.
9. Reuckers DF, van Jaarsveld CHM, Knoop H, et al. Exploring the long-term impact of chronic Q fever and Q fever fatigue syndrome on psychosocial functioning: a comparison with diabetes and the general population. J Psychosom Res 2019; 121:37–45.
10. Magnus P, Gunnnes N, Tveito K, et al. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine. Vaccine 2015; 33:8173–7.
11. Lunn MJH, Wing YK, Yu MWM, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors long-term follow-up. Arch Intern Med 2009; 169:2142–7.
12. Augustin M, Schommers P, Stecher M, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur 2021; 1:610122.
13. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021; 11:16144. doi:10.1038/s41598-021-95565-8.
14. Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry 2003; 160:221–36.
15. Clark MR, Katon W, Russo J, Kith P, Sintay M, Buchwald D. Chronic fatigue: risk factors for symptom persistence in a 2 1/2-year follow-up study. Am J Med 1995; 98:187–95.
16. Joyce J, Hotopf M, Wessely S. The prognosis of chronic fatigue and chronic fatigue syndrome: a systematic review. QJM 1997; 90:223–33.
17. Wynberg E, van Willigen HDG, Dijkstra M, et al. Evolution of COVID-19 symptoms during the first 12 months after illness onset. Clin Infect Dis. 2021; ciab759. doi:10.1093/cid/ciaa759.
18. ISARIC. Clinical data collection – the COVID-19 case report forms (CRFs). https://isaric.iris.org/research/covid-19-clinical-research-resources/covid-19-crf/.
19. Alberts M, Smets EM, Vercoulen JH, Garsen B, Bleijenberg G. “Abbreviated Fatigue Questionnaire”: a practical tool in the classification of fatigue. Ned Tijdschr Geneeskd 1997; 141:1526–30.
20. Pensao A, van Deuren S, Worm-Smetink M, et al. Short Fatigue Questionnaire: screening for severe fatigue. J Psychosom Res 2020; 137:110229.
21. World Health Organization. COVID-19 clinical management: living guidance. 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2.
22. Sromik K, Kulu-Glasgow I, Agymmetric C. The utility of “country of birth” for the classification of ethnic groups in health research: the Dutch experience. Ethnicity Health 2009; 14:255–69.
23. Centraal Bureau voor de Statistiek. Migratieachtergrond. Available at: https://www.cbs.nl/nl-nl/onze-diensten/methoden/begrippen/migratieachtergrond
Accessed November 22, 2021.
24. OECD. DAC list of ODA recipients 2021. Available at: https://www.oecd.org/dac/financing-sustainable-development/development-finance-standards/daclist.htm. Accessed November 22, 2021.
25. Goertz YMJ, Braamse AMJ, Spruit MA, et al. Fatigue in patients with chronic disease: results from the population-based Lifelines Cohort Study. Sci Rep 2021; 11:20977.

26. Peiris S, Mesa H, Aysola A, et al. Pathological findings in organs and tissues of patients with COVID-19: a systematic review. PLoS One 2021; 16:e0250708.

27. Osuchowski MF, Winkler MS, Skirecki T, et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med 2021; 9:622–42.

28. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 2021; 8:416–27.

29. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397:220–32.

30. Arnett SV, Allewa LM, Korossy-Horwood R, Clark IA. Chronic fatigue syndrome—a neuroimmunological model. Med Hypotheses 2011; 77:77–83.

31. Hardt J, Buchwald D, Wilks D, et al. Health-related quality of life in patients with chronic fatigue syndrome: an international study. J Psychosom Res 2001; 51:431–4.

32. Reynolds KJ, Vernon SD, Bouchery E, Reeves WC. The economic impact of chronic fatigue syndrome. Cost Eff Resour Alloc 2004; 2:4.

33. Vercoulen JHMM, Swanink CMA, Fennis JFM, et al. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 1994; 38:383–92.

34. Haktanir A, Can N, Seki T, Kurnaz MF, Dilmaç B. Do we experience pandemic fatigue? current state, predictors, and prevention. Curr Psychol. 2021; 1–12. doi:10.1007/s12144-021-02397-w. Epub ahead of print. PMID: 34690475; PMCID: PMC8527300.